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Purpose
Fluoropyrimidine-based combination chemotherapy, in combination with either oxaliplatin or
irinotecan, has demonstrated efficacy and tolerability in treatment of advanced colorectal
cancer (ACC).
Materials and Methods
Between January 2006 and December 2007, a total of 478 ACC patients were treated with
combination chemotherapy in first-line settings. Combination therapies included: 5-fluo-
rouracil, folinic acid plus oxaliplatin (FOLFOX, n=172), 5-fluorouracil, folinic acid plus irinotecan
(FOLFIRI, n=95), capecitabine plus oxaliplatin (XELOX, n=155), and capecitabine plus irino-
tecan (XELIRI, n=56). FOLFOX and FOLFIRI were repeated every 2 weeks, whereas XELOX and
XELIRI were repeated every 3 weeks until occurrence of disease progression or un-
acceptable toxicity, or until a patient chose to discontinue treatment.
Results
The median age was 58 years (range, 19 to 84 years) and the median chemotherapy
durations for FOLFOX, FOLFIRI, XELOX, and XELIRI were 4.9, 4.5, 5.7, and 5.4 months,
respectively. Combination chemotherapy regimens were generally well tolerated. The esti-
mated median progression-free-survival (PFS) for all patients was 6.8 months (95%
confidence interval, 6.3 to 7.3 months). No statistically significant difference in PFS was
found among regimens used as first-line chemotherapy. Sixty percent (n=290) of patients
received second or further lines of therapy after failure.
Conclusion
Fluoropyrimidine-based combination chemotherapy regimens appear to be equally active
and tolerable as first-line therapy for ACC.
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Colorectal adenocarcinoma is the fourth most frequently diag-
nosed malignancy in Korea, accounting for 12% of newly diagnosed
cancer cases. According to the Ministry of Health and Welfare, the
incidence of colorectal cancer has increased in both males and
females during the past 2 decades [1]. Although surgery is potentially
curative, approximately one third of all newly diagnosed patients
present with inoperable metastatic disease. Palliative chemotherapy
is more effective than the best supportive care for improving overall
survival (OS) as well as quality of life in advanced colorectal cancer
[2]. While significant advances have been made in recent years, cure
is rarely possible in advanced colorectal cancer (ACC), making
further improvements in therapy imperative. For more than three
decades, the treatment options for ACC have been almost exclusively
based on 5-fluorouracil (5-FU) and folinic acid (FA) [3]. Until the
early 1990s, 5-FU, often modulated by FA, was the single effective
chemotherapy available, but only led to meaningful responses in a
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small minority of treated patients. The recent integration of oxa-
liplatin and irinotecan for the management of ACC patients has
extended median OS in a meaningful way. Both drugs have been
shown to have synergistic effects with 5-FU and FA in colorectal
cancer cell lines [4,5]. Since irinotecan and oxaliplatin have been
used for ACC treatment, the efficacy of palliative chemotherapy for
ACC has considerably improved.
First-line treatment with irinotecan and either bolus or infusional
5-FU/FA, namely irinotecan/bolus fluorouracil/LV or 5-fluorouracil,
folinic acid plus irinotecan (FOLFIRI), significantly improved out-
comes as compared with 5-FU/FA [6,7]. Similarly, a combination of
oxaliplatin and infusional 5-FU/FA, known as 5-fluorouracil, folinic
acid plus oxaliplatin (FOLFOX), significantly increased the res-
ponse rate and the time to progression compared with 5-FU/FA [8].
These results established 5-FU-based chemotherapy, in combination
with either irinotecan or oxaliplatin, as standard first-line chemo-
therapy regimens for patients with ACC.
Capecitabine is an oral fluoropyrimidine designed to mimic a
continuous infusion of 5-FU. Capecitabine is considered to be as
effective and more tolerable than 5-FU [9]. Furthermore, capecitabine
has been shown to exhibit antitumor activity against ACC both as a
single agent [10,11] and in combination with oxaliplatin [12-14], as
well as with irinotecan [15]. In Korea, capecitabine was approved in
January 2006 as a partner with oxaliplatin or irinotecan for the
treatment of ACC.
A decision regarding chemotherapy regimens for an individual
patient can be a common clinical situation. Factors considered in-
clude the extent of disease, potential toxicities, especially for those
with impaired oral intake or with decreased performance status,
activity of chemotherapy, and the patient preference. The present
evaluation was done to plan and develop optimal treatment for Korean
patients. We therefore decided to evaluate various combination
chemotherapy regimens as first-line chemotherapy for ACC.
Materials and Methods
This report describes a single-center, retrospective study. Between
January 2006 and December 2007, a total of 537 ACC patients were
treated with first-line chemotherapy for advanced disease at
Samsung Medical Center (Seoul, Korea). Fifty-nine patients were
excluded because they were treated with single-agent chemo-
therapy. The criteria for case inclusion were as follows; 1) histolo-
gically confirmed diagnosis of adenocarcinoma arising from colon
or rectum, 2) no prior chemotherapy or radiotherapy except for
adjuvant use, 3) advanced (metastatic and/or recurrent) disease, 4)
availability of clinical data at the beginning of therapy and follow-
up. We attempted to exclude patients who were enrolled in clinical
trials to ensure the choice of chemotherapy regimen was solely at
the discretion of the treating physician. We collected follow-up
patient data from the Samsung Medical Center cancer registry. All
the data were prospectively recorded and only the survival data was
updated at the time of analysis. Written informed consent was given
by all patients prior to receiving chemotherapy, according to insti-
tutional guidelines. Approval of the study was obtained from the
Institutional Review Board.
The patients were required to have a life expectancy of 12 weeks
of more; age of at least 18 years or older; Eastern Cooperative
Oncology Group (ECOG) performance status of 2 or lower; adequate
hematologic (neutrophil countĥ1,500/mm
3 and platelet countĥ
100,000/mm
3), hepatic (serum total bilirubin levelģ1.5 mg/dL and
aspartate aminotransferase/alanine aminotransferaseģ3upper
limit normal) and renal (serum creatinine levelģ1.5 mg/dL) fun-
ctions. Our department guidelines define combination chemotherapy
regimens as follows: In FOLFOX or FOLFIRI, FA is given at the
dose of 200 mg/m
2 followed by bolus 5-FU 400 mg/m
2 on day 1, and
a 46-hour continuous infusion of 5-FU 2,400 mg/m
2 on days 1 and 2.
Oxaliplatin 85 mg/m
2 or irinotecan 180 mg/m
2 was administered on
day 1 as a 2-hour infusion, concurrent with FA. In capecitabine plus
oxaliplatin (XELOX) and capecitabine plus irinotecan (XELIRI),
oxaliplatin 130 mg/m
2 or irinotecan 240 mg/m
2 was given on day 1
in combination with oral capecitabine 1,000 mg/m
2 twice daily on
days 1 to 14. FOLFOX and FOLFIRI were repeated every 2 weeks,
whereas XELOX and XELIRI were repeated every 3 weeks until
disease progression or unacceptable toxicity occurred, or until a
patient chose to discontinue treatment. The dosages for subsequent
cycles were adjusted according to the toxic effects that developed
during the preceding cycle. All patients received a standard supportive
regimen consisting of hydration and antiemetics. The prophylactic
use of hematopoietic growth factors was not allowed during treatment,
except for patients with febrile neutropenia or grade 4 myelo-
suppression at the treating physician’s discretion. After this com-
bination chemotherapy had failed, second-line chemotherapy was
recommended to all the patients if their performance status was
preserved. According to department policies, all tumor measure-
ments were assessed every 2 or 3 cycles of chemotherapy by using
an abdominopelvic computed tomography (CT) scan and other tests
that were initially used to stage the tumor. Tumor response and
progression were evaluated according to the Response Evaluation
Criteria for Solid Tumors (RECIST) [16]. Toxicity grading was based
on the National Cancer Institute Common Toxicity Criteria (ver. 3).
The primary endpoint of this retrospective study was progression-
free survival (PFS). OS, response rate and tolerability were secondary
endpoints. The starting point of PFS was the first day of chemo-
therapy. The date of disease progression or death from causes other
than ACC was used in calculating PFS. PFS and OS were estimated
according to the Kaplan-Meier method and the statistical signi-
ficance of differences in survival curves between groups was tested
with a log-rank test. Multivariate models were used for exploratory
purposes to examine the impact of each regimen on the outcomes of
chemotherapy. Covariates included were age (below vs.median),
gender, previous adjuvant therapy, an ECOG performance status (0-Cancer Res Treat. 2011;43(2):96-101
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1 vs.2), number of involved sites (1 vs.2), metastases (liver,
peritoneum, and lung), baseline chemistry profiles (serum albumin,
alkaline phosphatase, and bilirubin), combination with bevacizumab,
and chemotherapy regimens. Laboratory parameters were initially
recorded as continuous variables and later dichotomized according
to the median value of each variable (below vs.median). All p-values
were two-sided, with pģ0.05 indicating statistical significance.
Results
Between January 2006 and December 2007, a total of 478 ACC
patients were treated with combination chemotherapy in a first-line
setting: FOLFOX (n=172), FOLFIRI (n=95), XELOX (n=155), and
XELIRI (n=56). In 29 patients, chemotherapy involved bevaci-
zumab. Baseline characteristics were balanced between patients
treated with each regimen (Table 1). The median age was 58 years
with a range of 19-84 years. Sixty percent of patients were male, and
33 patients (7%) had an ECOG performance status of 2 or more.
More than half of the patients (n=263) had received surgery for
curative intent, and 206 patients received adjuvant chemotherapy or
chemoradiotherapy. Approximately one-third of the patients had
two or more metastatic disease sites, mostly involving liver and
abdominal lymph nodes. We noted that more FOLFIRI or XELIRI
patients had received adjuvant therapy involving oxaliplatin than
FOLFOX or XELOX patients. After first-line failure, second-line
chemotherapy was administered for more than half of the patients
(n=290). Median follow-up duration was 40.6 months (95% con-
fidence interval [CI], 39.3 to 41.8 months). At the time of data
collection, 449 (89%) patients had progressed and 190 (40%) were
known to have died.
Median chemotherapy durations for FOLFOX, FOLFIRI,
XELOX, and XELIRI were 4.9, 4.5, 5.7 and 5.4 months, respectively.
We found no statistically significant difference among chemo-
therapy durations for these regimens (log-rank p=0.19). The most
common reason for discontinuation of treatment was disease pro-
gression. In 172 patients receiving FOLFOX, two-thirds of patients
discontinued therapy due to disease progression (n=118), phy-
FOLFOX FOLFIRI XELOX XELIRI
No. of patients 172 95 155 56
Bevacizumab combined 8 6 10 5
Age (yr)
Median 58 57 59 56
Range 31-78 19-79 26-80 28-77
Gender
Male 101 65 85 36
Female 71 30 70 20
ECOG performance status
0-1 163 89 143 50
29 6 1 2 6
Site of origin
Colon 110 61 101 31
Rectum 60 34 54 24
Both 2 0 0 1
Prior therapy
a)
Curative resection 88 70 78 27
Palliative resection 16 12 16 16
Adjuvant therapy 60 66 49 31
Involved site(s)
Abdominal lymph nodes 75 44 69 32
Liver 43 35 46 18
Lung 13 7 3 3
Peritoneum 11 10 9 8
Bone 3 8 9 1
Ovary 4 7 3 1
Table 1. Patient characteristics
FOLFOX, 5-fluorouracil, folinic acid plus oxaliplatin; FOLFIRI, 5-fluorouracil, folinic acid plus irinotecan; XELOX, capecitabine plus oxaliplatin; XELIRI, capecitabine plus
irinotecan; ECOG, Eastern Cooperative Oncology Group. 
a)Because patients could receive multiple prior treatments, the total number of prior therapies is different from the number
of patients.Soon Il Lee, et al_First-Line Chemotherapy for CRC
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sician’s recommendation or patient withdrawal (n=33), or toxicity
(n=21). FOLFIRI patients discontinued therapy due to progression
(n=60), physician's recommendation or patient withdrawal (n=13),
toxicity (n=20), or unknown causes (n=2). Similarly, disease pro-
gression was the most common cause of therapy discontinuation in
101 XELOX patients and 34 XELIRI patients.
Overall, all of the combination chemotherapy regimens were
generally well tolerated. We found no relevant difference in the
occurrence of overall grade 3 or 4 toxicities among regimens (Table 2).
In brief, the main difference in grade 3 or 4 toxicities with FOLFIRI
or XELIRI was diarrhea (21% for FOLFIRI and 27% for XELIRI
vs. 11% for FOLFOX and 9% for XELOX; p=0.02), and with
FOLFOX or XELOX the difference involved peripheral neuropathy
(9% for FOLFOX and 7% for XELOX vs. 2% for FOLFIRI and
XELIRI; pģ0.01). Although patients who were treated with
irinotecan-containing chemotherapy more frequently experienced
grade 3 or 4 leukopenia (13% vs. 10%; p=0.09) than those treated
with oxaliplatin-containing regimens, we found no significant
difference in the incidence of febrile neutropenia (5% in each arm).
In addition, grade 2 or more hand-foot syndrome was more
frequently observed in XELOX and XELIRI (14% and 12%,
respectively) than in FOLFOX and FOLFIRI (6% and 8%, res-
pectively). In the current retrospective analysis, seven possible
treatment-related deaths were identified. One death occurred in the
midst of treatment with FOLFOX, with no clinical evidence of pro-
gression having been demonstrated. Another patient died of res-
piratory failure shortly after completion of the second FOLFOX
cycle, in which the possibility of disease progression could not be
completely excluded. The patient, initially presenting with multiple
pulmonary nodules and bilateral pleural effusion, complained about
increasing dyspnea and suffered a sudden respiratory arrest. Five
other deaths occurred in patients while receiving FOLFIRI or
XELOX, and were attributed to neutropenic sepsis.
Of a total of 478 patients, 61 could not be evaluated for responses
because of the absence of any measurable lesions or early discon-
tinuation of therapy. Objective responses to chemotherapy were
noted in 200 patients (response rate, 48%; 95% CI, 43 to 53%); 42%
for FOLFOX, 49% for FOLFIRI, 55% for XELOX, and 51% for
XELIRI. The difference in the response rates for each regimen was
not statistically significant (p=0.09). Patients who had a poor per-
Table 2. Grade 3 or 4 toxicities per patient
FOLFOX FOLFIRI XELOX XELIRI
(n=172) (n=95) (n=155) (n=56)
Anemia 22 (13) 16 (17) 21 (14) 7 (13) 
Leukopenia 17 (10) 13 (14) 14 (9) 7 (13)
Thrombocytopenia 5 (3) 5 (5) 6 (4) 3 (5)
Nausea 14 (8) 9 (10) 11 (7) 6 (11)
Vomiting 14 (8) 7 (7) 13 (8) 7 (13)
Stomatitis 9 (5) 7 (7) 14 (9) 6 (11)
Diarrhea 19 (11) 20 (21) 14 (9) 15 (27)
Hand-foot syndrome 7 (4) 5 (5) 15 (10) 6 (11)
Sensory neuropathy 15 (9) 2 (2) 11 (7) 1 (2)
Values are presented as number (%). FOLFOX, 5-fluorouracil, folinic acid plus oxaliplatin; FOLFIRI, 5-fluorouracil, folinic acid plus irinotecan; XELOX, capecitabine plus
oxaliplatin; XELIRI, capecitabine plus irinotecan.
Table 3. Summary of chemotherapy outcomes
FOLFOX FOLFIRI XELOX XELIRI
(n=172) (n=95) (n=155) (n=56)
Treatment duration (mo)
Median 4.9 4.5 5.7 5.4
95%CI 4.0-6.0 3.1-5.9 4.4-7.1 3.5-7.2
Response rates
% 42 49 55 51
95%CI 34-50 39-59 46-62 38-64
Progression-free survival (mo)
Median 6.2 6.0 7.9 7.1
95%CI 5.3-7.2 4.5-7.6 6.6-9.2 5.1-9.0
FOLFOX, 5-fluorouracil, folinic acid plus oxaliplatin; FOLFIRI, 5-fluorouracil, folinic acid plus irinotecan; XELOX, capecitabine plus oxaliplatin; XELIRI, capecitabine plus
irinotecan; CI, confidence interval.Cancer Res Treat. 2011;43(2):96-101
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formance status (2 in ECOG scale) were significantly less likely
to respond to first-line chemotherapy (24% vs. 50%; pģ0.01) com-
pared to those with an ECOG performance status of 0 or 1. Response
rate was not significantly influenced by age, gender, prior treatments,
baseline laboratory parameters, metastatic sites, or chemotherapy
regimen. Also, combination of bevacizumab did not affect response
rate.
The estimated median PFS for all patients was 6.8 months (95%
CI, 6.3 to 7.3 months), and the median OS was not yet reached. PFS
was shorter, although statistically insignificant (p=0.12), in patients
receiving FOLFOX or FOLFIRI (6.2 months and 6.0 months, res-
pectively) than those receiving XELOX (7.9 months) or XELIRI
(7.1 months). Chemotherapy outcomes are summarized in Table 3.
One-year PFS rates for FOLFOX, FOLFIRI, XELOX, and XELIRI
were 24%, 21%, 32%, and 32%, respectively (Fig. 1). A multivariate
regression model revealed that PFS was significantly affected by
performance status (hazard ratio, 0.39; 95% CI, 0.28 to 0.57; p
ģ0.01). We also tested whether the PFS was modified by interaction
between the effect of baseline clinical parameters and the
chemotherapy regimens; the first-level interaction term between
these variables was entered into a separate multivariate model.
However, we found no interaction between any first-line chemo-
therapy regimens for each clinical parameter.
Discussion
Despite recent advances in the treatment of ACC [17], patients
treated with first-line chemotherapy have a median OS rarely
exceeding 24 months. In the current analysis, outcomes for ACC are
comparable to those in the published trials of combination chemo-
therapy. There appears to be no advantage of one combination
regimen over the others. Our observation that PFS was slightly
shorter with FOLFOX or FOLFIRI than with XELOX or XELIRI is
possibly related to negative prognostic factors influencing the choice
of intravenous chemotherapeutic agents instead of oral agents. ACC
patients who already had peritoneal dissemination seldom could
tolerate oral agents. Similarly, the choice of a chemotherapeutic agent
depends on the ones previously used in the adjuvant setting. Although
this study is retrospective in nature, the results provide a piece of
evidence that patients with ACC may derive an indisputable benefit
from fluoropyrimidine-based combination chemotherapy. The deci-
sion to use specific chemotherapeutic agent(s) in patients with ACC
should be determined by their relative merits on a case-by-case basis.
The evolution of treatment using irinotecan and oxaliplatin in
combination with 5-FU regimens has resulted in a significant
prolongation of life in patients with ACC. Since both drugs have
demonstrated similar activity in first- and second-line settings, the
optimal chemotherapy regimen and dosing schedule in patients with
ACC remains undecided [18]. Randomized trials comparing first-
line FOLFOX with FOLFIRI indicated equivalent activity and
moderate toxicity differences between these two regimens [19],
suggesting that use of either oxaliplatin or irinotecan is reasonable.
In another phase III study in which patients crossed over to the
alternative regimen upon progression while on their first-line regimen,
the overall PFS on first-line therapy was 8.1 months for FOLFOX
and 8.5 months for FOLFIRI [20]. In a combined analysis of seven
phase III trials in ACC, Grothey et al. [21] reported that the strategy
of making these three active drugs (fluoropyrimidine, oxaliplatin,
and irinotecan) available to patients with ACC could maximize OS.
In addition to efficacy data, patient convenience and satisfaction
are assuming increased importance in cancer management. Oral
administration has the advantage of permitting convenient, patient-
orientated therapy, providing the patient with a degree of indepen-
dence and improved quality of life, while avoiding complications
associated with intravenous drug administration. Furthermore, most
patients prefer orally administered therapy to intravenous treatment
[22]. Chemotherapy regimens involving oral capecitabine showed
similar safety and efficacy profiles compared with 5-FU-based
regimens [23]. Oral capecitabine was proved to have a similar
quality of life profile to that of 5-FU [24], but seemed to be more
convenient in terms of administration. 
In Korea, a capecitabine-containing regimen was approved in
January 2006 as the first-line treatment of ACC. Data from the
current retrospective study suggest that patients are highly compliant
with capecitabine, when given in combination with either oxaliplatin or
irinotecan. Response rates and PFS were similar between FOLFOX-
/FOLFIRI and XELOX/XELIRI. Patients treated with capecitabine
experienced a higher incidence of clinically relevant hand-foot
syndrome, but this toxic effect was predictable and manageable.
An improved understanding of the molecular pathogenesis of
cancer has lead to the development of novel agents designed to

















Fig. 1. Progression-free survival. FOLFOX, 5-fluorouracil, folinic
acid plus oxaliplatin; FOLFIRI, 5-fluorouracil, folinic acid plus
irinotecan; XELOX, capecitabine plus oxaliplatin; XELIRI, capeci-
tabine plus irinotecan.Soon Il Lee, et al_First-Line Chemotherapy for CRC
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approaches in the treatment of ACC involves therapeutic agents that
inhibit the neovascularization process of growing tumors [25].
Bevacizumab is a recombinant humanized anti-vascular endothelial
growth factor monoclonal antibody that is being clinically evaluated
in many tumor types, including ACC. Because bevacizumab was
only recently made available in Korea as first-line chemotherapy,
only 29 patients received bevacizumab.
Conclusion
This study confirms that both oxaliplatin- and irinotecan-con-
taining combination chemotherapy are effective for the first-line
treatment of ACC. Capecitabine clearly represents an effective and
well-tolerated oral alternative to 5-FU. While the current study was
primarily focused on cytotoxic therapies, the integration of targeted
agents, including bevacizumab, is a novel standard option to further
improve outcomes for patients with ACC.
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